sabeluzole

01/01/2005 - "Placebo data were pooled from two 1-year, randomized, double-blind, placebo-controlled trials of sabeluzole in patients with mild-to-moderate Alzheimer disease (AD). "
08/01/1997 - "In this study, sabeluzole (5 or 10 mg twice daily vs. placebo) was investigated in patients with probable Alzheimer's disease over 1 year, with assessments of cognitive performance and structural changes. "
08/01/1997 - "Cognitive outcome measures suggest that sabeluzole may have potential in slowing the cognitive deterioration of Alzheimer's disease. "
08/01/1997 - "Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates."
01/01/1992 - "The single- and repeated-dose pharmacokinetics of sabeluzole have been determined in six elderly patients with [senile] dementia of the Alzheimer type. "

09/01/1989 - "An additional protective effect of R 58735 upon reperfusion in severe ischemia experiments may explain the difference between the two compounds."
09/01/1989 - "A clear difference, however, was observed between nifedipine and R 58735 upon severe ischemia, where R 58735 produced a significantly greater protection of functional, but not of biochemical parameters. "
09/01/1989 - "In the guinea pig heart-lung preparation, the protective effects of nifedipine and R 58735 on cardiovascular alterations following mild (35 min) and severe (60 min) ischemia and reperfusion (30 min) were studied. "
09/01/1989 - "Protective activity of nifedipine and R 58735 upon damage caused by global ischemia in the guinea pig heart-lung preparation."
09/01/1989 - "Nifedipine and R 58735 were equi-protective against the effects of mild ischemia with respect to functional (LVP, dp/dt, and cardiac output) and biochemical (ATP, CrP, and adenylate charge) parameters. "

01/01/1993 - "The second group--open study--consisting of 26 patients suffering from polyneuropathy of various origin, treated by sabeluzole 3 x 10 mg/d. "
01/01/1993 - "[Treatment of polyneuropathy using sabeluzole]."
11/01/1992 - "Thirty-seven non-IDDM patients at an early stage of polyneuropathy, defined as the presence of symptoms for less than two years, as well as an abnormal perception threshold and/or abnormal thermal discrimination threshold, were treated with sabeluzole, a new antihypoxic drug, or placebo for 1 year in a double-blind, placebo-controlled study. "

11/01/1992 - "The results of the present study show no beneficial effect of sabeluzole on peripheral nerve function in patients at an early stage of diabetic polyneuropathy."
11/01/1992 - "Antihypoxic treatment at an early stage of diabetic neuropathy: an electrophysiological study with sabeluzole."
11/01/1993 - "Efficiency of the antihypoxic substance sabeluzole in patients with clinically and neurophysiologically evident diabetic polyneuropathy."
04/01/1993 - "Author trie to prove a possible positive effect of sabeluzole in patients with diabetic polyneuropathy. "
04/01/1993 - "[EMG findings in patients with diabetic polyneuropathy treated with sabeluzole]."

05/01/1996 - "A double-blind, randomized trial of sabeluzole--a putative glutamate antagonist--in obstructive sleep apnea."
05/01/1996 - "The effect of sabeluzole (SAB), an agent with anti-excitatory amino acid activity, on sleep, breathing and daytime symptoms was investigated in 13 patients with obstructive sleep apnea (OSA). "